Veal, G.J.; Tweddle, D.A.; Visser, J.; Errington, J.; Buck, H.; Marange, J.; Moss, J.; Joseph, S.; Mulla, H.
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. Cancers 2021, 13, 1868.
https://doi.org/10.3390/cancers13081868
AMA Style
Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H.
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. Cancers. 2021; 13(8):1868.
https://doi.org/10.3390/cancers13081868
Chicago/Turabian Style
Veal, Gareth J., Deborah A. Tweddle, Johannes Visser, Julie Errington, Helen Buck, Josephine Marange, Jon Moss, Shiju Joseph, and Hussain Mulla.
2021. "Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial" Cancers 13, no. 8: 1868.
https://doi.org/10.3390/cancers13081868
APA Style
Veal, G. J., Tweddle, D. A., Visser, J., Errington, J., Buck, H., Marange, J., Moss, J., Joseph, S., & Mulla, H.
(2021). Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. Cancers, 13(8), 1868.
https://doi.org/10.3390/cancers13081868